A public-private working group has been set up based on the Japanese health ministry’s pharma industry vision issued last year, with its first meeting held earlier this month to collect the views of trade associations on the current state and…
To read the full story
Related Article
- Japan Unveils New Pharma Industry Vision, 1st Update in 8 Years
September 14, 2021
REGULATORY
- Ishin Proposes Adding Drug, Device Makers to Chuikyo, LDP Wary
June 10, 2026
- ONODERA GT’s Parkinson’s Gene Therapy Gets Sakigake Tag
June 10, 2026
- Cabinet Approves Immunization Act Revision to Cover Antibody Drugs
June 10, 2026
- LDP Lawmakers Seek Routine HPV Vaccinations for Males by April 2027
June 10, 2026
- MHLW Lifts Part of Approval Conditions for Takeda’s Vyvanse
June 9, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





